Pharmaceutical policies for gaining access to high-priced medicines

A comparative analysis between England and Brazil

Bibliographic Data

ID5335071
AuthorsGil Vicente (0000-0002-2758-4320, Universidade Federal de Santa Catarina, corresponding author), Michael Calnan (0000-0002-7239-6898, University of Kent), Norberto Rech Bonetti (0000-0003-4808-4277, Universidade Federal de Santa Catarina), Silvana Nair Leite (0000-0002-5258-9684, Universidade Federal de Santa Catarina)
Year2022
Volume46
Issue134
Pages886-905
Publication date2022-01-01
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueSaúde em Debate (JOURNAL)
Journal identifiersISSN: 0103-1104 • E-ISSN: 2358-2898
PublisherFapUNIFESP (SciELO) (PUBLISHER)
DOI10.1590/0103-1104202213422
OpenAlexW4312352616
SCIELO_PIDS0103-11042022000300886
LanguageEN
Citations received1
References cited44

Although the National Health Service (NHS) and the Unified Health System (SUS) are systems with similar universal principles, they can show different political measure patterns in the pharmaceutical field. This paper aimed to provide a comparative analysis of pharmaceutical policies highlighting strategies to guarantee access and sustainability to High-Price Medicines (HPMs) in Brazil and England. We performed an integrative literature review in electronic databases, supplemented by grey literature searched on governmental platforms (laws, decrees, ordinances, and resolutions). A total of Forty-seven articles and seven policies were selected and categorized for analysis. The results showed that both countries apply distinct policies to ensure access to HPMs, among them, policies to define price and reimbursement and actions to regulate the use inside the system. Also, these countries apply distinct policies to their sustainability as local partnerships for product development in Brazil and confidential managed agreements with multinational industries in the England. In conclusion, despite similarities in principles, these countries have been proposing and applying distinct pharmaceutical policies to maintain access and ensure the sustainability of their health systems

Access to medicines · Business · Confidentiality · Developing country · Economic growth · Economics · Geography · Grey literature · Health care · Market access · MEDLINE · Multinational corporation · Pharmaceutical policy · Political science · Product (mathematics) · Public economics · Reimbursement · Service (business) · Sustainability · Finance · Health Systems, Economic Evaluations, Quality of Life · Law · Marketing · Pharmaceutical Economics and Policy · Public Health in Brazil · Health Policy

Tools

Open DOIOpen Access